Virginia G. de Yebenes

Virginia G. de Yebenes

Auto-generated profile, based on publicly available information

Virginia G. de Yebenes

Department of Immunology, Ophthalmology and ENT, Universidad Complutense de Madrid, Madrid, Spain.

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2008 in Journal of Experimental Medicine
Verified
Journal Article
Open access
VYVirginia G. de YébEnes
Virginia G. de YébEnes
LBLaura Belver
Laura Belver
DPDavid G. Pisano
David G. Pisano
SGSusana GonzálEz
Susana GonzálEz
Aranzazu VillasanteAranzazu Villasante
Aranzazu Villasante
ARAlmudena R. Ramiro
Almudena R. Ramiro
Activated B cells reshape their primary antibody repertoire after antigen encounter by two molecular mechanisms: somatic hypermutation (SHM) and class switch recombination (CSR). SHM and CSR are initiated by activation-induced cytidine deaminase (AID) through the deamination of cytosine residues on the immunoglobulin loci, which leads to the generation of DNA mutations or double-strand break intermediates. As a bystander effect, endogenous AID levels can also promote the generation of chromosome translocations, suggesting that the fine tuning of AID expression may be critical to restrict B cell lymphomagenesis. To determine whether microRNAs (miRNAs) play a role in the regulation of AID expression, we performed a functional screening of an miRNA library and identified miRNAs that regulate CSR. One such miRNA, miR-181b, impairs CSR when expressed in activated B cells, and results in the down-regulation of AID mRNA and protein levels. We found that the AID 3′ untranslated region contains multiple putative binding sequences for miR-181b and that these sequences can be directly targeted by miR-181b. Overall, our results provide evidence for a new regulatory mechanism that restricts AID activity and can therefore be relevant to prevent B cell malignant transformation.

1 November 2010 in Immunity
Verified
Journal Article
Closed access
LBLaura Belver
Laura Belver
VYVirginia G. de Yébenes
Virginia G. de Yébenes
ARAlmudena R. Ramiro
Almudena R. Ramiro

1 October 2020 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
PDF file
VYVirginia G. de Yébenes
Virginia G. de Yébenes
ABAna M. Briones
Ana M. Briones
IMInmaculada Martos-Folgado
Inmaculada Martos-Folgado
SMSonia M. Mur
Sonia M. Mur
JOJorge Oller
Jorge Oller
ARAlmudena R. Ramiro
Almudena R. Ramiro
Objective: microRNAs are master regulators of gene expression with essential roles in virtually all biological processes. miR-217 has been associated with aging and cellular senescence, but its role in vascular disease is not understood. Approach and Results: We have used an inducible endothelium-specific knock-in mouse model to address the role of miR-217 in vascular function and atherosclerosis. miR-217 reduced NO production and promoted endothelial dysfunction, increased blood pressure, and exacerbated atherosclerosis in proatherogenic apoE −/ − mice. Moreover, increased endothelial miR-217 expression led to the development of coronary artery disease and altered left ventricular heart function, inducing diastolic and systolic dysfunction. Conversely, inhibition of endogenous vascular miR-217 in apoE −/− mice improved vascular contractility and diminished atherosclerosis. Transcriptome analysis revealed that miR-217 regulates an endothelial signaling hub and downregulates a network of eNOS (endothelial NO synthase) activators, including VEGF (vascular endothelial growth factor) and apelin receptor pathways, resulting in diminished eNOS expression. Further analysis revealed that human plasma miR-217 is a biomarker of vascular aging and cardiovascular risk. Conclusions: Our results highlight the therapeutic potential of miR-217 inhibitors in aging-related cardiovascular disease.

26 January 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ÁÁÁngel F. Álvarez-Prado
Ángel F. Álvarez-Prado
PPPablo Pérez-Durán
Pablo Pérez-Durán
APArantxa Pérez-García
Arantxa Pérez-García
ABAlberto Benguria
Alberto Benguria
CTCarlos Torroja
Carlos Torroja
ARAlmudena R. Ramiro
Almudena R. Ramiro
Activation-induced deaminase (AID) initiates antibody diversification in germinal center (GC) B cells through the deamination of cytosines on immunoglobulin genes. AID can also target other regions in the genome, triggering mutations or chromosome translocations, with major implications for oncogenic transformation. However, understanding the specificity of AID has proved extremely challenging. We have sequenced at very high depth >1,500 genomic regions from GC B cells and identified 275 genes targeted by AID, including 30 of the previously known 35 AID targets. We have also identified the most highly mutated hotspot for AID activity described to date. Furthermore, integrative analysis of the molecular features of mutated genes coupled to machine learning has produced a powerful predictive tool for AID targets. We also have found that base excision repair and mismatch repair back up each other to faithfully repair AID-induced lesions. Finally, our data establish a novel link between AID mutagenic activity and lymphomagenesis.

1 August 2004 in Virology
Verified
Journal Article
Closed access
CHCarolina Hurtado
Carolina Hurtado
AGAitor G Granja
Aitor G Granja
MBMarı́a J Bustos
Marı́a J Bustos
MNMarı́a L Nogal
Marı́a L Nogal
GBGonzalo González de Buitrago
Gonzalo González de Buitrago
ACAngel L Carrascosa
Angel L Carrascosa

2 April 2013 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
VYVirginia G de Yébenes
Virginia G de Yébenes
NBNahikari Bartolomé‐Izquierdo
Nahikari Bartolomé‐Izquierdo
ARAlmudena R. Ramiro
Almudena R. Ramiro